Gramicidin
Antimicrobial / TopicalAlso known as: Gramicidin D, Gramicidin A/B/C
Mechanism
One of the very first antibiotics ever discovered (1939, by Rene Dubos). A linear peptide from soil bacteria that kills bacteria by forming tiny ion channels in their membranes, letting ions leak out uncontrollably. Too toxic for injection but widely used topically — it's one of the three active ingredients in Neosporin (alongside neomycin and polymyxin B). A staple of first-aid kits worldwide.
Technical detail
Linear pentadecapeptide (15 amino acids with alternating D- and L-configurations) from Bacillus brevis (now Aneurinibacillus migulanus). Gramicidin D is a mixture: 80% gramicidin A, 5% B, 15% C (differ at position 11: Trp/Phe/Tyr). Folds into a beta-6.3 helix — two monomers form a head-to-head dimer spanning the lipid bilayer, creating a cation-selective channel (3.5-4.0 Å pore). Conducts monovalent cations (Na+, K+, H+) at ~10^7 ions/sec, collapsing ion gradients and membrane potential. Kills gram-positive bacteria rapidly. Too hemolytic for systemic use (LD50 IV: ~2 mg/kg in mice). Historically significant: among the first antibiotics used clinically (1939, treating wound infections in WWII soldiers).
Effects
ANTIMICROBIAL MECHANISM: Linear pentadecapeptide antibiotic produced by Bacillus brevis. Unique mechanism: gramicidin D (the commercial mixture of gramicidins A, B, and C) forms ion channels in bacterial cell membranes. Two gramicidin molecules dimerize in a head-to-head β-helical conformation, spanning the lipid bilayer and creating a monovalent cation-selective channel (2.6 Å pore diameter). This channel allows uncontrolled flux of H+, Na+, K+, and other monovalent cations across the membrane, dissipating the proton motive force and electrochemical gradient, leading to rapid cell death. This is one of the most well-characterized ion channels in biophysics — gramicidin has been a model system for studying membrane ion transport since the 1970s. SPECTRUM: Gram-positive organisms: Staphylococcus aureus, Streptococcus pyogenes, S. pneumoniae, and other Gram-positive cocci and bacilli. Limited Gram-negative activity (outer membrane blocks access). Active against some Gram-negatives when outer membrane is disrupted (combination with polymyxin B in Neosporin addresses this). MIC BREAKPOINTS: No CLSI/EUCAST breakpoints (topical use only). Topical concentrations vastly exceed MICs. RESISTANCE: Ion channel mechanism makes resistance development difficult — would require fundamental membrane composition changes. Some resistance via increased membrane lipid rigidity or altered phospholipid composition. Rare in clinical practice. PHARMACOKINETICS: TOPICAL ONLY — gramicidin is far too toxic for systemic use. It would form ion channels in human cell membranes (RBCs, kidney, liver, heart cells), causing hemolysis and multi-organ failure. Hemolytic at very low concentrations (in vitro). When applied topically, minimal systemic absorption through intact or even mildly damaged skin — the molecule's hydrophobicity limits diffusion into aqueous tissue compartments. CLINICAL APPLICATIONS: Component of triple antibiotic formulations: Polysporin Ophthalmic = gramicidin + polymyxin B (no bacitracin due to ophthalmic irritation). Neosporin Original = bacitracin + neomycin + polymyxin B (gramicidin not in standard Neosporin). Gramicidin ophthalmic solutions — used for bacterial conjunctivitis and keratitis. Sofradex® (dexamethasone + framycetin + gramicidin) — ophthalmic/otic drops used widely in UK/Commonwealth countries. BIOPHYSICS SIGNIFICANCE: Gramicidin is one of the most studied molecules in biophysics. The gramicidin channel has been used to understand: ion selectivity, single-channel conductance, membrane-peptide interactions, and lipid bilayer mechanics. Over 10,000 biophysics publications reference gramicidin. Nobel Prize-relevant work on ion channels has used gramicidin as a model system. TOXICITY (Topical): Very low toxicity when applied topically. Rare allergic contact dermatitis. Ocular irritation is uncommon with properly formulated ophthalmic preparations. SYSTEMIC TOXICITY (if inadvertently absorbed): Hemolysis, nephrotoxicity, hepatotoxicity — gramicidin channels form in all cell membranes. Never use systemically, IV, IM, or by any route that allows systemic exposure.
Practitioner Guide
CLINICAL PEARLS — OPHTHALMOLOGY AND WOUND CARE PERSPECTIVE: OPHTHALMIC USE (PRIMARY CLINICAL APPLICATION): Gramicidin is used mainly in ophthalmic formulations because bacitracin (the alternative Gram-positive topical) is poorly soluble in aqueous solutions and its ointment form causes visual blurring. Gramicidin is water-soluble and can be formulated as eye drops. Gramicidin + polymyxin B ophthalmic solution: covers Gram-positives (gramicidin) + Gram-negatives (polymyxin B) — broad-spectrum topical coverage for bacterial conjunctivitis, blepharitis, and corneal ulcers. Dosing: 1-2 drops q4-6h to affected eye(s) for 7-10 days. Sofradex® (gramicidin + framycetin + dexamethasone): popular combination in UK, Australia, and many other countries for otitis externa and bacterial conjunctivitis with inflammation. NOT for use if tympanic membrane is perforated (ototoxicity risk from framycetin/aminoglycoside component). WOUND CARE: Gramicidin is less commonly used than bacitracin for topical wound care. In formulations where it appears (certain compounded preparations), it provides Gram-positive coverage through the unique ion channel mechanism. Not typically selected as monotherapy — usually combined with polymyxin B and/or other agents. WHAT MAKES GRAMICIDIN SPECIAL: The ion channel mechanism is fundamentally different from every other antibiotic. Bacteria cannot easily develop resistance because they would need to change their membrane composition in ways incompatible with survival. This makes gramicidin a useful component of combination products — it kills through a completely orthogonal mechanism. LIMITATIONS: (1) Too toxic for systemic use — this is an absolute limitation, not a dose-optimization problem. (2) Gram-positive only (needs combination for Gram-negative coverage). (3) Limited to topical/ophthalmic routes. (4) Less versatile than bacitracin (which comes in ointment form suitable for wounds). SAFETY COUNSELING: Explain to patients that gramicidin eye drops may cause mild transient stinging. If using Sofradex-type combinations with steroids, monitor for steroid-related complications (IOP elevation, cataracts) with prolonged use >2 weeks. Discontinue if signs of fungal superinfection (steroid component can mask/promote). Do not use gramicidin-containing products near the ear canal if TM perforation is suspected (framycetin/aminoglycoside ototoxicity risk in combinations). STORAGE: Ophthalmic solutions — store at room temperature or refrigerated per manufacturer. Discard opened bottles after 28 days (typical ophthalmic standard). Protect from light.
Research Summary
TIER 1 (Gold Standard): FDA-approved as component of OTC topical/ophthalmic antibiotic formulations (predates modern trial requirements). Gramicidin ophthalmic formulations have extensive post-marketing safety data spanning 60+ years. No modern randomized trials specifically for gramicidin (established agent, minimal commercial interest in new trials). TIER 2 (Strong): Hladky & Haydon, 1972 — ion channels formed by gramicidin in lipid bilayers (Nature, PMID: 4553060 — foundational biophysics paper). Ketchem et al., 1997 — high-resolution NMR structure of gramicidin A channel in lipid bilayer (Science, PMID: 9171846). Wallace, 2000 — comprehensive review of gramicidin channels (BioEssays). DrugBank DB00027. Over 10,000 biophysics publications using gramicidin as a model ion channel. TIER 3 (Moderate): Clinical experience from ophthalmologists using gramicidin-containing drops (routine clinical practice, not formally published). Sofradex clinical experience from UK/Commonwealth countries (decades of use). Compendial data from USP/BP/EP monographs. International regulatory dossiers. Post-marketing surveillance from global OTC use. KEY FINDINGS: (1) Gramicidin's ion channel mechanism is one of the best-understood in all of biology. (2) Topical/ophthalmic use is safe and effective. (3) Systemic toxicity absolutely precludes parenteral or oral use. (4) The orthogonal killing mechanism (ion channels vs. cell wall) makes it valuable in combination products. (5) Resistance is rare due to the fundamental nature of the membrane target. GAPS: Modern comparative RCTs for ophthalmic formulations. Resistance surveillance (not routinely performed). Whether gramicidin analogs could be designed for systemic use (academic interest — engineered variants with selectivity for bacterial over mammalian membranes). Nanotechnology-based delivery systems for expanded applications. ACTIVE TRIALS: Primarily academic biophysics research on gramicidin channel variants. Limited clinical trials for new formulations.